Get the Stockscreener App
3.805
4.40%
0.165
Rocket Pharmaceuticals Inc stock is traded at $3.805, with a volume of 1.36M.
It is up +4.40% in the last 24 hours and down -19.66% over the past month.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
See More
Previous Close:
$3.64
Open:
$3.68
24h Volume:
1.36M
Relative Volume:
0.42
Market Cap:
$414.12M
Revenue:
-
Net Income/Loss:
$-223.12M
P/E Ratio:
-1.8935
EPS:
-2.0095
Net Cash Flow:
$-190.49M
1W Performance:
+5.56%
1M Performance:
-19.66%
6M Performance:
-10.38%
1Y Performance:
-41.81%
1-Day Range:
$3.68
$3.88
1-Week Range:
$3.46
$3.88
52-Week Range:
$2.19
$8.26
Rocket Pharmaceuticals Inc Stock (RCKT) Company Profile
Name
Rocket Pharmaceuticals Inc
Sector
Industry
Phone
646-440-9100
Address
350 FIFTH AVENUE, NEW YORK, NY
Compare RCKT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RCKT
Rocket Pharmaceuticals Inc
|
3.795 | 397.21M | 0 | -223.12M | -190.49M | -2.0095 |
VRTX
Vertex Pharmaceuticals Inc
|
440.33 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
747.42 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
842.47 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
335.49 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
315.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Rocket Pharmaceuticals Inc Stock (RCKT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Downgrade | JP Morgan | Neutral → Underweight |
| Aug-20-25 | Upgrade | BofA Securities | Neutral → Buy |
| Jul-25-25 | Downgrade | BofA Securities | Buy → Neutral |
| May-30-25 | Downgrade | Evercore ISI | Outperform → In-line |
| May-28-25 | Downgrade | Goldman | Neutral → Sell |
| May-28-25 | Downgrade | JP Morgan | Overweight → Neutral |
| May-28-25 | Downgrade | Jefferies | Buy → Hold |
| May-28-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| May-28-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-27-25 | Downgrade | Needham | Buy → Hold |
| May-27-25 | Downgrade | TD Cowen | Buy → Hold |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Dec-30-24 | Initiated | Wedbush | Outperform |
| Dec-18-24 | Initiated | Jefferies | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Apr-02-24 | Initiated | Goldman | Neutral |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-01-23 | Initiated | Morgan Stanley | Overweight |
| Nov-08-22 | Initiated | Canaccord Genuity | Buy |
| Nov-01-22 | Initiated | BTIG Research | Buy |
| Jul-08-22 | Initiated | Raymond James | Outperform |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Mar-02-21 | Initiated | Stifel | Buy |
| Feb-18-21 | Initiated | Needham | Buy |
| Dec-16-20 | Initiated | UBS | Buy |
| Dec-08-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Jul-02-20 | Initiated | JP Morgan | Overweight |
| Jun-25-20 | Resumed | BofA/Merrill | Buy |
| Jun-01-20 | Resumed | Oppenheimer | Outperform |
| Nov-06-19 | Initiated | Chardan Capital Markets | Buy |
| Sep-26-19 | Initiated | Piper Jaffray | Overweight |
| Apr-23-19 | Initiated | Robert W. Baird | Outperform |
| Mar-15-19 | Initiated | BofA/Merrill | Buy |
| Feb-05-19 | Initiated | Oppenheimer | Outperform |
| Sep-13-18 | Initiated | Ladenburg Thalmann | Buy |
| Jul-10-18 | Initiated | William Blair | Outperform |
View All
Rocket Pharmaceuticals Inc Stock (RCKT) Latest News
Needham Maintains Rocket Pharmaceuticals(RCKT.US) With Hold Rating - Moomoo
Activity Recap: Is Rocket Pharmaceuticals Inc Equity Warrant a cyclical or defensive stock2026 News Drivers & Consistent Return Strategy Ideas - baoquankhu1.vn
Meme Stocks: Can Rocket Pharmaceuticals Inc expand into new markets2026 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Big Picture: Will Rocket Pharmaceuticals Inc benefit from sector rotationQuarterly Portfolio Summary & High Accuracy Investment Entry Signals - baoquankhu1.vn
RCKT stock dives despite gene therapy approval — Wall Street dismisses sell-off - MSN
Volume Report: Can Rocket Pharmaceuticals Inc deliver consistent EPS growth2026 Stock Rankings & AI Forecast Swing Trade Picks - baoquankhu1.vn
Aug Ideas: Is Rocket Pharmaceuticals Inc exposed to political risk2026 Winners & Losers & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
RCKT Technical Analysis | Trend, Signals & Chart Patterns | ROCKET PHARMACEUTICALS INC (NASDAQ:RCKT) - ChartMill
[ARS] ROCKET PHARMACEUTICALS, INC. SEC Filing - Stock Titan
Rocket Pharmaceuticals (NASDAQ: RCKT) seeks vote on director slate and option exchange - Stock Titan
Rally Mode: Is Rocket Pharmaceuticals Inc stock a good dividend stockPrice Action & Technical Confirmation Alerts - baoquankhu1.vn
US premarket movers: Argan, Rocket Pharmaceuticals, Unity - MSN
Rocket gene therapy, among FDA’s March approvals, earns PRV - biocentury.com
[SC TO-C] ROCKET PHARMACEUTICALS, INC. Tender Offer Communication | RCKT SEC FilingForm SC TO-C - Stock Titan
FDA Grants Accelerated Approval to Rocket Pharma’s Gene Therapy Kresladi for LAD-I - The Indian Practitioner
RCKTW SEC FilingsROCKET PHARMACEUTICALS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Rocket Pharmaceuticals Inc (9IP1.DU) valuation measures and financial statistics - Yahoo Finance UK
First Therapy Funded by California Taxpayer Dollars is Approved to Treat Rare Childhood Disorder - Noticias Newswire
Momentum Shift: What are Rocket Pharmaceuticals Incs growth levers2026 Action & Fast Entry High Yield Tips - baoquankhu1.vn
Rocket Pharmaceuticals, Inc. $RCKT Shares Acquired by JPMorgan Chase & Co. - MarketBeat
Why Rocket Pharmaceuticals (RCKT) got a commercial boost from FDA approval of KRESLADI - MSN
Aug Analyst Calls: Can Rocket Pharmaceuticals Inc expand into new markets2026 Market Overview & Verified Momentum Stock Alerts - baoquankhu1.vn
Rocket Pharmaceuticals Inc (9IP1.DU) Interactive Stock Chart - Yahoo! Finance Canada
RCKT: B of A Securities Raises Price Target on Buy Rating | RCKT Stock News - GuruFocus
Buyback Watch: Is Rocket Pharmaceuticals Inc Equity Warrant forming a breakout pattern2026 Setups & Accurate Technical Buy Alerts - baoquankhu1.vn
Risks Report: Is Rocket Pharmaceuticals Inc forming a bullish divergenceTrade Performance Summary & Growth-Oriented Investment Plans - baoquankhu1.vn
RCKT Stock Down Despite FDA Nod to Gene Therapy in Rare Disease - The Globe and Mail
Rocket Pharmaceuticals Files $400M Mixed Shelf Offering, Opens Financing Doors - timothysykes.com
Bank of America Forecasts Strong Price Appreciation for Rocket Pharmaceuticals (NASDAQ:RCKT) Stock - MarketBeat
RCKT Shares Fall Even After FDA Approves Gene Therapy for Uncommon Disease - Bitget
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI - Insider Monkey
FDA Approval Makes Rocket Pharma Gene Therapy the First for Ultra-Rare Immune Disorder - MedCity News
Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy - Yahoo Finance
Aug Analyst Calls: Whats the beta of Rocket Pharmaceuticals Inc Equity Warrant stock2026 Sector Review & Smart Money Movement Tracker - baoquankhu1.vn
Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited - Seeking Alpha
Rocket Pharma rises as FDA approves gene therapy - MSN
Assessing Rocket Pharmaceuticals (RCKT) Valuation After Accelerated FDA Approval Of KRESLADI - Sahm
Rocket Pharmaceuticals Delivers Bold Moves Amid Volatile Market - timothysykes.com
A Quick Look at Today's Ratings for Rocket Pharmaceuticals(RCKT.US), With a Forecast Between $9 to $16 - Moomoo
FDA approves Rocket Pharma’s Kresladi for severe LAD-I - thepharmaletter.com
Rocket Pharmaceuticals Faces A Make-Or-Break FDA Call On KRESLADI - Finimize
BofA raises Rocket Pharmaceuticals price target on execution view By Investing.com - Investing.com Canada
Rocket Has Liftoff With Kresladi Approval, But Market Remains Small - insights.citeline.com
FDA approves Rocket’s Kresladi as first gene therapy for LAD-I - BioWorld MedTech
Rocket Pharmaceuticals (RCKT) Stock Pops on Historic FDA Gene Therapy Win - MEXC Exchange
Leerink raises Rocket Pharmaceuticals stock price target on FDA approval By Investing.com - Investing.com Canada
Rocket Pharmaceuticals (RCKT) Stock Surges After FDA Approves Groundbreaking Gene Therapy - MEXC
RCKT Stock Dives Despite Gene Therapy Approval — Wall Street Dismisses Sell-Off - Stocktwits
Rocket Pharmaceuticals Inc Stock (RCKT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Rocket Pharmaceuticals Inc Stock (RCKT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Shah Gaurav | CEO |
Feb 18 '26 |
Sale |
3.34 |
5,990 |
19,995 |
1,046,055 |
| Wilson Martin | General Counsel |
Feb 18 '26 |
Sale |
3.34 |
1,376 |
4,593 |
682,000 |
| Wilson Martin | General Counsel |
Feb 13 '26 |
Sale |
3.31 |
12,253 |
40,582 |
683,376 |
| Militello John | See Remarks |
Feb 13 '26 |
Sale |
3.31 |
3,726 |
12,341 |
92,176 |
| Shah Gaurav | CEO |
Feb 13 '26 |
Sale |
3.31 |
12,279 |
40,668 |
1,052,045 |
2.11%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):